Case Studies

Helping Patients to Stand With HPP: Creating a Community-Focused Website For Alexion and its Patients


Hypophosphatasia (HPP) is a rare genetic condition that adversely affects the development of healthy bones. Patients with HPP have soft or weakened bones that can result in skeletal deformities, fractures, dental issues, and pain. Patients with HPP can also have brain, muscle, joint, lung, and kidney problems. HPP can have devastating physical effects that impact the daily lives of those suffering from it. Healthcare professionals typically focus on providing treatments for the physical manifestations of a disease and may not fully understand the emotional and psychological tolls HPP can have on patients and caregivers. Alexion recognized that patients living with HPP, as well as their families and caregivers, had limited resources available for information and support. These patients also had no online forums for sharing their experiences or fostering a sense of community. Furthermore, much of the information available portrayed the condition in an overwhelming or frightening fashion.

Click here to read full article in PDF format.

Congress Booth Innovation for Biogen

Biogen, a biotechnology company traditionally known for its multiple sclerosis treatments, wanted to make improvements to its Medical Affairs booth for the 2018 American Academy of Neurology (AAN) Annual Meeting. At the 2017 meeting, the company presented medical content in the following multiple disease states in its booth: multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer’s disease (AD). However, the Biogen senior leadership team believed the booth to be too sterile, as it included a substantial amount of white space and appeared sparse to attendees. Additionally, the booth was too segmented between the MS, SMA, and AD disease states and did not effectively highlight the breadth of Biogen’s capabilities in neuroscience.

Click here to read full article in PDF format.

Augmented Reality (AR) Salesforce Training

Viscira was charged with creating an innovative digital learning solution to elevate Actelion’s internal salesforce Phase II training from “memorizing to meaningful.” The training program was required to incorporate disease education curriculum on PAH* that included the effects of PAH on the heart and lungs and PAH drug classifications. The training solution also needed to deepen the learner’s empathy and understanding of the patient journey for those suffering with PAH.

This unique augmented reality (AR) learning program was created for new sales representatives at Actelion who are participating in the initial training/onboarding process. Most of this audience was expected to have minimal previous knowledge of PAH or the pathophysiology of the disease. The previous curriculum comprised highly scientific, written material that learners were required to read and try to memorize.

Actelion wanted to take a new, fresh approach to training that would increase learning effectiveness. By integrating immersive technology based on AR into the curriculum, Viscira brought more contextually relevant information to help the new sales representatives gain a much better understanding of the disease and the core data versus simply memorizing the material.

Click here to read full article in PDF format.

Disease Education Website for Agios Pharmaceuticals

In conjunction with Agios’ unbranded disease education campaign, focused on helping healthcare professionals to identify isocitrate dehydrogenase (IDH) mutations in patients, Viscira was challenged to redesign and relaunch the Agios disease education website known as

The goals of the disease education campaign were as follows:

  1. To raise awareness among healthcare professionals of the relevance of IDH mutations in patients with hematologic malignancies and solid tumors, with a specific focus on patients diagnosed with acute myeloid leukemia (AML).
  2. To motivate healthcare professionals to test their patients for IDH mutations and to help them find an appropriate clinical trial.

In addition to the above goals, the specific goal related to the website relaunch was to:

  1. Identify the most effective user experience to begin to position as the go-to disease education site for IDH in AML and solid tumors in a rapidly evolving therapeutic space.

Click here to read full article in PDF format.